Thymosin alpha-1 protocol — the house schedule in mg and clicks

What Thymosin alpha-1 is and what it is studied for

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from the thymus, the gland where T-cells mature. In research settings it is studied for immune modulation — the maturation and activity of T-cells, dendritic-cell function and the balance of the immune response — rather than for simply stimulating it. It has a long research history, including in settings where the immune system is under-performing, and it is one of the better-characterised peptides in the library.

The house protocol is unusual for how little it changes: 1.6 mg on Monday and Thursday, every week, for eight weeks. There is no run-in, because the dose is the dose; there is no step-up, because the window note names one amount and one frequency. The general research window runs 0.5–3 mg per dose, but the house ceiling is the 1.6 mg it schedules, and the per-week maximum is two injections.

Who it suits — and who should not run it

Written for the adult researcher with a pattern rather than a diagnosis: frequent minor infections, slow recovery from them, a chronically high training or travel load that keeps knocking the immune system flat, or a planned stretch — a competition block, a long trip — where resilience matters. It is also written for the researcher whose inflammatory picture has an immune component their physician has already looked at. The house exclusions:

Not for

• A diagnosed autoimmune condition without the explicit agreement of the physician managing it — immune modulation cuts both ways.
• An organ transplant, or any immunosuppressive medication, for the same reason.
• Active cancer or a recent cancer history, outside a physician-led setting.
• Pregnant, breastfeeding, or planning pregnancy in the next 6 months.
• Under 18.

Start gate: a baseline full blood count with differential is in hand and nothing on it needs a physician's attention first.

The house protocol

Twice weekly, subcutaneous in the abdomen a hand's width from the navel, alternating sides each dose, at the same time of day — morning works for most researchers. Monday and Thursday are the house days because they split the week evenly. One pen = 300 clicks at 16.7 mcg per click; 1.6 mg is 96 clicks, so a pen holds three doses with a dozen clicks spare.

One phase. The dose does not change across the cycle, and the frequency does not change either. Eight weeks is the house cycle length for a first run; longer is a personalised-protocol decision.

Click total: 16 doses × 96 = 1,536 clicks → 6 pens (1,800 clicks), leaving 264 clicks — about 4.4 mg, nearly three doses — at the end of the cycle. A 96-click dose is a long turn of the dial; count it, and start a fresh pen when fewer than 96 clicks remain rather than splitting a dose across two pens.

Thymosin alpha-1 is well tolerated in the research literature. Mild redness at the site is the usual report; a brief feeling of being slightly off-colour in the day after an early dose is reported by some researchers and generally fades. Fever, a rash or anything that looks like an allergic reaction is a stop-and-call. Keep the pen in the fridge between uses.

Week by week — what people typically notice and when

The compound modulates; it does not replace the basics. Sleep 7–9 hours — the immune system does most of its maintenance at night — and keep the training load honest: a block of overreaching in the middle of the cycle will show up in the log as exactly the thing the pen was supposed to prevent. Keep the symptom log simple: a line a day on sleep, energy and anything brewing.

Labs we ask for before and during

The baseline differential is the gate, not a formality: a count that is already unusual belongs with a physician before any immune-modulating compound is added. Low vitamin D or ferritin at baseline gets corrected first, because either one explains a lot of "I catch everything" on its own. Vitamin D, magnesium and omega-3 are the only general supplements.

Stacking: what it pairs with

Thymosin alpha-1 is the immune corner of the library and pairs with compounds working on other axes. Alongside KPV it covers both halves of an inflammatory picture — immune modulation and gut-lining inflammation — and alongside the KLOW pen it is the one addition that does not duplicate anything already in the click. It sits comfortably next to the repair pens — Wolverine, BPC-157, TB-500 — for the researcher whose slow healing has an immune component.

For the researcher coming off burnout or a travel-heavy stretch, the NAD+ and epithalon pages describe the energy and reset side of the same problem. Any stack moves the week-8 lab repeat from a good idea to a requirement.

Common mistakes

• Adding a third dose in a bad week. Two a week is the ceiling. A cold is not a reason to change the schedule.
• Skipping the baseline differential. It is the one lab that can say "not this compound, not yet".
• Running it with an autoimmune condition on your own. Immune modulation in the wrong direction is a physician-level decision.
• Splitting a dose across two pens. Start a fresh pen when fewer than 96 clicks remain.
• Overreaching in training because you feel resilient. The log will show you exactly where that went wrong.
• Expecting to feel it. The result is the infection that did not happen and the week-8 labs — not a sensation.